CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As disclosed previously on a Current Report on Form 8-K filed with the Securities and Exchange Commission on March20, 2017, Marc Becker, Senior Vice President and Chief Financial Officer of CRISPR Therapeutics AG (the “Company”), took a family and medical leave of absence.Mr.Becker will not resume his duties as the Company’s principal financial officer or principal accounting officer. He will be transitioning his remaining responsibilities at the Company over the coming months and will be leaving his functions at the Company as of September30, 2017.

As disclosed previously on a Current Report on Form 8-K filed with the Securities and Exchange Commission on March20, 2017, Samarth Kulkarni, Ph.D., the Company’s President and Chief Business Officer will continue to serve as the Company’s acting principal financial officer and Michael Esposito, the Company’s Senior Director, Controller, will continue to serve as the Company’s acting principal accounting officer, in each case, until such time as the Company hires Mr.Becker’s replacement.

The Company’s Board of Directors has begun the search for the Company’s next Chief Financial Officer, and will work with a leading executive search firm to assist in identifying and evaluating candidates.

About CRISPR THERAPEUTICS AG (NASDAQ:CRSP)

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.